Shares of the clinical-stage biotech Geron Corporation (NASDAQ:GERN) are up by double digits for the second day in a row on no apparent news. What’s going on?
While the company hasn’t released any material news this week to explain this sudden move higher, Geron’s stock might be responding to two recent developments:
Congress passed a so-called....More>>>
Kamada Ltd. (NASDAQ:KMDA) – Stock analysts at Jefferies Group dropped their FY2020 earnings estimates for shares of Kamada in a research report issued on Tuesday, May 15th. Jefferies Group analyst R. Denhoy now anticipates that the biotechnology company will earn $0.61 per share for the year, down from their previous forecast of $0.62. Jefferies Group also issued estimates for Kamada’s....More>>>
&l;p&g;Last month I found 37 mutual fund managers who have proved their skill (in my view) by outperforming the S&a;amp;P 500&a;nbsp;over the last decade by enough make a real difference for shareholders. Of these, 16 managers run funds that don&s;t charge a load and are still open to new investors.&a;nbsp; These are the managers I am using to&a;nbsp;demonstrate the results&a;nbsp;of investing with&a;nbsp;great....More>>>
Sio Capital Management LLC lifted its position in shares of Viking Therapeutics Inc (NASDAQ:VKTX) by 2.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,276,845 shares of the biotechnology company’s stock after purchasing an additional 26,595 shares during the quarter. Viking Therapeutics makes up....More>>>
Dividend growth investing can be a great way to boost your passive income over time. To do it right, though, you have to find stocks that can both grow their dividends faster than inflation and have sustainable free cash flows for the long haul.
Gilead Sciences (NASDAQ:GILD), a blue chip biotech stock, meets both of these critical criteria. Even so, this top biotech is rarely considered purely....More>>>
Washington’s increased scrutiny of technology giants could spell trouble for their stocks, if history is any guide.
Technology is the least regulated industry sector, with just 27,000 regulations versus 215,000 for manufacturing and 128,000 for the financial sector, according to Bank of America Merrill Lynch. That light touch could change in the wake of Facebook’s consumer data....More>>>
Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.
Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.
Several other brokerages have also recently weighed in on SRPT. UBS cut Sarepta....More>>>
Vical (NASDAQ:VICL) has been a horror show for investors. Failed trials, poor technology and a lack of awareness have left this small biotech company from San Diego all but forgotten. There are many reasons that a long-term investor would have no interest in this company even though it passes Benjamin Graham’s criteria as a net-net investment because it is trading below cash. I believe there....More>>>
Histogenics (NASDAQ:HSGX) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 9th. Analysts expect Histogenics to post earnings of ($0.25) per share for the quarter.
Histogenics (NASDAQ:HSGX) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter,....More>>>
Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “buy” rating reaffirmed by Mizuho in a research note issued to investors on Wednesday. They presently have a $45.00 price target on the biotechnology company’s stock. Mizuho’s price objective would suggest a potential upside of 31.39% from the company’s current price.
The analysts wrote, “We estimate....More>>>
Editor’s note: Seeking Alpha is proud to welcome The Sensible Steward as a new contributor. It’s easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
About Protalix (PLX)
Protalix is a development-stage biotech company based in Carmiel, Israel.....More>>>
The share price of Biocon gained as much as 1.77 percent in morning on Thursday after receiving the EU GMP certification for its sterile drug product manufacturing facility.
“We have received the European Union Good Manufacturing Practice (GMP) certification for the sterile drug product manufacturing facility in Bangalore,” the biotechnology major said in its filing on Wednesday.
If an ounce of prevention is worth a pound of cure, how much is a cure worth? Specifically, how much is a cure worth as compared to treating a disease on an ongoing basis? This is a question that the healthcare industry now must tackle.
Biopharmaceutical companies are making more progress than ever before at not just treating diseases but developing cures for the diseases. The possibility....More>>>
As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…
Pharmaceutical Stock Current Share Price April 2017 Gain
Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%